Diamyd Medical, a company that develops precision medicine therapies for Type 1 Diabetes, announced on Friday that it has added Karin Rosen, MD, PhD to its Board of Directors as an adjunct member, and to be proposed for election to the board at its next General Meeting of Shareholders.

Dr Rosen has over 20 years' experience that includes clinical research and development and building, leading and successfully introducing multiple novel medicines in the United States and globally.

She has served in dual roles as the Chief Scientific Officer and Executive Vice President of R&D at Horizon Therapeutics (acquired by Amgen). She has held the position of senior vice president, US medical affairs at GlaxoSmithKline, senior vice president, US and global medical affairs at Aimmune Therapeutics, Inc. (aquired by Nestle) and a member of the clinical development leadership team working on the Phase 2b-3/4 clinical programs and filing strategies for US. Food and Drug Administration and European Medicines Agency. She has worked as therapeutic area head, immunology, at Genentech.

Ulf Hannelius, CEO of Diamyd Medical, said: "We are thrilled to welcome Dr. Rosen to Diamyd Medical at this transformative period of the Company. Karin Rosen's extensive drug development and commercial launch experience spanning a wide variety of indications including immunology, oncology, respiratory and infectious diseases will be invaluable for Diamyd Medical."